表紙
市場調查報告書
商品編碼
1063083

基礎胰島素(長效胰島素)的全球市場(2021年∼2028年)

Global Basal Insulin (Long-Acting Insulin) Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 165 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球基礎胰島素(長效胰島素)市場相關調查分析,提供市場動態,產業分析,市場分析,競爭情形等系統性資訊。

目錄

第1章 全球基礎胰島素(長效胰島素)市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球基礎胰島素(長效胰島素)市場-市場定義和概要

第3章 全球基礎胰島素(長效胰島素)市場-摘要整理

  • 市場明細:各產品類型
  • 市場明細:應用
  • 市場明細:各地區

第4章 全球基礎胰島素(長效胰島素)市場-市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球基礎胰島素(長效胰島素)市場-產業分析

  • 波特的五力分析
  • 流行病學分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球基礎胰島素(長效胰島素)市場-COVID-19分析

  • 市場COVID-19分析
    • COVID-19前的市場方案
    • 目前COVID-19市場方案
    • COVID-19後的市場方案/未來市場方案
  • COVID-19的價格的動態
  • 需求與供給的頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 全球基礎胰島素(長效胰島素)市場:各產品類型

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%):各產品類型
    • 市場魅力指數:各產品類型
  • Lantus*
    • 簡介
    • 市場規模分析,100萬美元(2019年∼2028年),及與前一年同期比較成長分析(%)(2020年∼2028年)
  • Levemir
  • Toujeo
  • Tresiba
  • Basaglar
  • Insulin Glargine的生物相似藥

第8章 全球基礎胰島素(長效胰島素)市場:各應用領域

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%):各應用領域
    • 市場魅力指數:各應用領域
  • 第一型糖尿病
    • 簡介
    • 市場規模分析,100萬美元(2019年∼2028年),及與前一年同期比較成長分析(%)(2020年∼2028年)
  • 第二型糖尿病

第9章 全球基礎胰島素(長效胰島素)市場:各地區

  • 簡介
    • 市場規模分析,100萬美元(2019年∼2028年),及與前一年同期比較成長分析(%)(2020年∼2028年):各地區
    • 市場魅力指數:各地區
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東和非洲

第10章 全球基礎胰島素(長效胰島素)市場-競爭情形

  • 主要的開發與策略
  • 企業佔有率分析
  • 產品的基準

第11章 全球基礎胰島素(長效胰島素)市場企業簡介

  • Biocon Limited*
    • 企業概要
    • 產品系列及說明
    • 主要亮點
    • 財務概要
  • Sanofi
  • Novo Nordisk
  • Eli Lilly

第12章 全球基礎胰島素(長效胰島素)市場-DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式
目錄
Product Code: DMPH4712

Market Overview

The global basal insulin (long-acting insulin) market size was valued at US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Basal insulin is a type of insulin that has a slow onset of action. People take it between meals and before bedtime to help control their blood sugar levels when they are not eating.

Market Dynamics

The factors that are expected to drive the global basal insulin (long-acting insulin)

the market is the increasing demand for the treatment of diabetes is expected to drive the market growth.

The increasing demand for the treatment of diabetes is expected to drive the market growth

Diabetes is widely regarded as a lifestyle disease. With the increase in population worldwide, the disease's incidence has increased over time. Approximately 100 million people worldwide require insulin, including all Type 1 diabetes and 10-25 percent of Type 2 diabetes. Because it acts as background insulin, basal insulin is an important component in diabetes management. It's intended to keep blood sugar stable during fasting periods, such as between meals and sleeping. Insulin aids in absorbing glucose in the bloodstream by the body's cells, providing the energy required. When there is a need for fuel, some of the glucose in the blood is stored in the liver and slowly formed and released into the bloodstream. Because people with type 1 diabetes do not produce their insulin, they must rely on basal insulin injections to keep their blood sugar under control. However, if one has type 2 diabetes, the body produces insulin. Lantus (insulin glargine) is the first long-acting insulin.

The side effects associated with basal insulin (long-acting insulin) is expected to hamper the market growth

Low blood sugar levels (hypoglycemia) can occur if one receives too much insulin for blood sugar in the body at any given time. Low blood sugar can cause fatigue, shakiness, irritability, and sweating. It can also cause the heart to beat irregularly. Gaining weight insulin facilitates the entry of blood sugar from food into cells for use as energy. However, if consume more calories than the body requires, the extra glucose in cells is stored and converted into a fat allergic reaction at the injection site.

Pain, redness, swelling, itching, or thickening of the injection site are common Lantus side effects. These side effects typically subside within a few days or weeks. Lantus dosage should be given subcutaneously (under the skin) once a day at the same time every day. The individual and the desired blood glucose levels determine the dose. Lantus may interact with other medications such as albuterol, clonidine, reserpine, or beta-blockers. Many other medications can either increase or decrease the effects of insulin glargine on blood sugar control.

COVID-19 Impact Analysis

Patients with endocrine disorders face unique challenges during the coronavirus disease 2019 (COVID-19) pandemic. Diabetes patients are at a higher risk of developing a more severe illness. COVID-19 appears to trigger severe diabetes manifestations such as diabetic ketoacidosis (DKA), hyperosmolar hyperglycemia (HHS), and severe insulin resistance. The role of hyperglycemia in the risk of severe infection in diabetic patients has received little attention. Diabetes is a risk factor for infection in general. Because COVID-19 can cause a severe inflammatory response, it has been difficult to determine whether hyperglycemia in COVID-19 is a cause or as appears more likely, a result of severe disease. Hence, Covid-19 is expected to positively impact the global basal insulin (long-acting insulin) market.

Segment Analysis

Lantus segment is expected to dominate the market growth in the market forecast period

Prescription Lantus is a long-acting insulin used to control high blood sugar in adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes. Lantus is a prescription medication sold under the brand name Lantus. It is used to treat type 1 diabetes in adults and children aged 6 years and older and type 2 diabetes in adults. Lantus contains the insulin glargine drug, which is long-acting insulin. It is administered just beneath the skin (a subcutaneous injection). The medication is packaged in 10-milliliter (mL) vials containing 100 units of insulin glargine per mL. The vial is used with needles, which are not included. Lantus is also available as a prefilled SoloStar pen. Each pen contains 3 mL of drug solution containing 100 units of insulin per mL.

Lantus is an FDA-approved medication used to treat type 2 diabetes in adults. Type 2 diabetes is a long-term (chronic) condition in which cells do not respond to insulin as well as they should. Insulin is a hormone that allows sugar to enter cells from the blood. Because cells do not respond properly to insulin, they do not receive the energy required to function properly. Furthermore, sugar levels in the blood rise. If left untreated, this can lead to serious complications like nerve damage. Some people with type 2 diabetes require insulin because their bodies stop producing insulin independently. Hence, the increasing demand for Lantus is expected to drive market growth in the forecast period.

Geographical Analysis

North America region is expected to hold the largest market share in the global basal insulin (long-acting insulin) market

The increasing incidence of diabetes and FDA approvals in this region is expected to drive market growth.

According to National Diabetes Statistics Report in 2018, US 34.2 million people of all ages had diabetes. It affected around 34.1 million adults aged 18 and up, or 13.0 percent of all adults in the United States. Furthermore, on July 29th, 2021, The U.S FDA approved the first interchangeable biosimilar insulin product, intended to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is biosimilar to and interchangeable with its reference product Lantus (insulin glargine), a long-acting insulin analogue. It is the first interchangeable biosimilar product approved for the treatment of diabetes in the United States.

Competitive Landscape

With mergers, collaborations, and product launches, the global basal insulin (long-acting insulin) market is highly competitive. Some of the key players are Novo Nordisk, Sanofi, Eli Lilly, Biocon Limited

Biocon Limited

Overview: Biocon Limited is a biopharmaceutical company headquartered in Bangalore, India. The company was founded in 1978. Generics, biosimilars, research services, and novel biologics are among the company's four global businesses.

Product Portfolio: The SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, are interchangeable in the United States to help control high blood sugar in adult and pediatric patients with type 1 diabetes, as well as adults with type 2 diabetes.

Key Developments: On 28th July 2021, SEMGLEE injection interchangeable biosimilars were launched by Biocon Biologics Ltd. and Viatris Inc.

Why Purchase the Report?

  • Visualize the composition of the global basal insulin (long-acting insulin) market segmentation by product type and application, highlighting the key commercial assets and players.
  • Identify commercial opportunities in the global basal insulin (long-acting insulin) market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global basal insulin (long-acting insulin) market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global basal insulin (long-acting insulin) market report would provide an access to an approx. 45+market data table, 40+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Basal Insulin (Long-Acting Insulin) Market- By Product Type

  • Lantus
  • Levemir
  • Toujeo
  • Tresiba
  • Basaglar
  • Insulin Glargine Biosimilars

Global Basal Insulin (Long-Acting Insulin) Market- By Application

  • Type 1 Diabetes
  • Type 2 Diabetes

Global Basal Insulin (Long-Acting Insulin) Market- By Region

  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East and Africa

Table of Contents

1. Global Basal Insulin (Long-Acting Insulin) Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Basal Insulin (Long-Acting Insulin) Market- Market Definition and Overview

3. Global Basal Insulin (Long-Acting Insulin) Market- Executive Summary

  • 3.1. Market Snippet By Product Type
  • 3.2. Market Snippet By Application
  • 3.3. Market Snippet By Region

4. Global Basal Insulin (Long-Acting Insulin) Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. The increasing demand for the treatment of diabetes
    • 4.1.2. Restraints:
      • 4.1.2.1. The side effects associated with basal insulin (long-acting insulin)
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Basal Insulin (Long-Acting Insulin) Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Basal Insulin (Long-Acting Insulin) Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Basal Insulin (Long-Acting Insulin) Market- By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Lantus*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Levemir
  • 7.4. Toujeo
  • 7.5. Tresiba
  • 7.6. Basaglar
  • 7.7. Insulin Glargine Biosimilars

8. Global Basal Insulin (Long-Acting Insulin) Market- By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Type 1 Diabetes
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Type 2 Diabetes

9. Global Basal Insulin (Long-Acting Insulin) Market- By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10. Global Basal Insulin (Long-Acting Insulin) Market- Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Global Basal Insulin (Long-Acting Insulin) Market Company Profiles

  • 11.1. Biocon Limited. *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Sanofi
  • 11.3. Novo Nordisk
  • 11.4. Eli Lilly

LIST NOT EXHAUSTIVE

12. Global Basal Insulin (Long-Acting Insulin) Market- DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us